These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32893130)

  • 1. Comparison of Two Pediatric-Inspired Regimens to Hyper-CVAD in Hispanic Adolescents and Young Adults With Acute Lymphoblastic Leukemia.
    Almanza-Huante E; Espinosa-Bautista K; Rangel-Patiño J; Demichelis-Gómez R
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):55-62.e2. PubMed ID: 32893130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of modified hyper-CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience.
    Jalaeikhoo H; Rajaeinejad M; Keyhani M; Zokaasadi M; Dehghani Firoozabadi MM
    Cancer Med; 2018 Mar; 7(3):594-599. PubMed ID: 29383863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Allogeneic HCT as Postremission Therapy for Transplant-Eligible Adult Lymphoblastic Leukemia/Lymphoma After Frontline Hyper-CVAD.
    Damlaj M; Snnallah M; Bashir R; Eddine IS; Alahmari B; Salama H; Alaskar A; Alhejazi A; Alzahrani M
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):690-696. PubMed ID: 32636149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Hyper-CVAD Regimen is an Optimal Pediatric-inspired Regimen for Adolescents and Adults With Acute Lymphoblastic Leukemia.
    Jabbour E; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):63-65. PubMed ID: 33191168
    [No Abstract]   [Full Text] [Related]  

  • 5. Hyper-CVAD Compared With BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective Single-Center Analysis.
    El-Cheikh J; El Dika I; Massoud R; Charafeddine M; Mahfouz R; Kharfan-Dabaja MA; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):179-185. PubMed ID: 27988194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of Hyper-CVAD/MA and CHALL-01 regimens in the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia patients under 60 years old].
    Huang AJ; Wang LB; Du J; Tang GS; Cheng H; Gong SL; Gao L; Qiu HY; Ni X; Chen J; Chen L; Zhang WP; Wang JM; Yang JM; Hu XX
    Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):625-632. PubMed ID: 31495127
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison between Hyper-CVAD and PETHEMA ALL-93 in Adult Acute Lymphoblastic Leukemia: A Single-Center Study.
    Erkut N; Akidan O; Selim Batur D; Karabacak V; Sonmez M
    Chemotherapy; 2018; 63(4):207-213. PubMed ID: 30304722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults.
    Guzauskas GF; Villa KF; Vanhove GF; Fisher VL; Veenstra DL
    J Adolesc Young Adult Oncol; 2017 Mar; 6(1):53-61. PubMed ID: 27779442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
    Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
    Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of the Hyper-CVAD with an institutional regimen for the treatment of acute lymphoblastic leukemia in adults in a hospital of Mexico].
    Ramos-Peñafiel CO; Cabrera-García Á; Rozen-Fuller E; González-León G; Balderas C; Kassack-Ipiña JJ; Castellanos-Sinco H; Martínez-Murillo C; Montaño-Figueroa E; Martínez-Tovar A; Olarte-Carrillo I; Santoyo-Sánchez A; Collazo-Jaloma J
    Rev Peru Med Exp Salud Publica; 2014; 31(3):525-9. PubMed ID: 25418653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
    Rytting ME; Thomas DA; O'Brien SM; Ravandi-Kashani F; Jabbour EJ; Franklin AR; Kadia TM; Pemmaraju N; Daver NG; Ferrajoli A; Garcia-Manero G; Konopleva MY; Cortes JE; Borthakur G; Garris R; Cardenas-Turanzas M; Schroeder K; Jorgensen JL; Kornblau SM; Kantarjian HM
    Cancer; 2014 Dec; 120(23):3660-8. PubMed ID: 25042398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen.
    Rytting ME; Jabbour EJ; Jorgensen JL; Ravandi F; Franklin AR; Kadia TM; Pemmaraju N; Daver NG; Ferrajoli A; Garcia-Manero G; Konopleva MY; Borthakur G; Garris R; Wang S; Pierce S; Schroeder K; Kornblau SM; Thomas DA; Cortes JE; O'Brien SM; Kantarjian HM
    Am J Hematol; 2016 Aug; 91(8):819-23. PubMed ID: 27178680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Dana Farber consortium protocol (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients <50 Y. Single institution experience.
    Alabdulwahab AS; Elsayed HG; Sherisher MA; Zeeneldin A; Alghamdi K; Elbjeirami WM
    Leuk Res; 2017 Sep; 60():58-62. PubMed ID: 28704720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the BFM Regimen Feasible for the Treatment of Adult Acute Lymphoblastic Leukemia? A Retrospective Analysis of the Outcomes of BFM and Hyper-CVAD Chemotherapy in Two Centers.
    Alacacioglu I; Medeni SS; Ozsan GH; Payzin B; Sevindik OG; Acar C; Katgi A; Ozdemirkan F; Piskin O; Ozcan MA; Undar B; Demirkan F
    Chemotherapy; 2014; 60(4):219-23. PubMed ID: 25871894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and outcome of the hyper-CVAD regimen in patients with adult acute lymphoblastic leukemia.
    Portugal RD; Loureiro MM; Garnica M; Pulcheri W; Nucci M
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):52-7. PubMed ID: 25037887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation.
    Jeong SH; Moon JH; Kim JS; Yang DH; Park Y; Cho SG; Kwak JY; Eom HS; Won JH; Hong JS; Oh SY; Lee HS; Kim SJ
    Ann Hematol; 2015 Apr; 94(4):617-25. PubMed ID: 25465233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
    Weiser MA; O'Brien S; Thomas DA; Pierce SA; Lam TP; Kantarjian HM
    Cancer; 2002 Jan; 94(2):285-91. PubMed ID: 11900213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
    Faderl S; Kantarjian HM; Thomas DA; Cortes J; Giles F; Pierce S; Albitar M; Estrov Z
    Leuk Lymphoma; 2000 Jan; 36(3-4):263-73. PubMed ID: 10674898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyper-CVAD regimen in routine management of adult acute lymphoblastic leukemia: a retrospective multicenter study.
    Buyukasik Y; Acar K; Kelkitli E; Uz B; Serefhanoglu S; Ozdemir E; Pamukcuoglu M; Atay H; Bektas O; Sucak GT; Turgut M; Aksu S; Yagci M; Sayınalp N; Ozcebe OI; Goker H; Haznedaroglu IC
    Acta Haematol; 2013; 130(3):199-205. PubMed ID: 23797290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of adult T-lymphoblastic lymphoma depends on ALL-type chemotherapy, prognostic factors, and performance of allogeneic hematopoietic stem cell transplantation.
    Hu M; Wang H; Wang L; Yang M; Lou Y; Jin J
    Medicine (Baltimore); 2018 Jul; 97(28):e11374. PubMed ID: 29995776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.